Feb 21 |
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
|
Feb 21 |
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
|
Jan 29 |
CareDX pares loss, gains after jury awards $96M to Natera in patent dispute (update)
|
Jan 27 |
CareDx Issues Statement in Patent Infringement Case
|
Jan 26 |
CareDX drops after jury votes in favor of Natera in patent fight (update)
|
Jan 22 |
CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 16% this week, taking three-year losses to 89%
|
Jan 11 |
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
|
Jan 9 |
CareDx sees FY24 revenue $279M-$280M above high end of guidance
|
Jan 9 |
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
|
Dec 28 |
CareDx's Turmoil: Risks Appear Priced In
|